AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00538733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle
Study NCT00538733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)
Study NCT00538733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)
Study NCT00002708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure
Study NCT00002708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00002708 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00002708 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Study NCT01971580 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Study NCT01229670 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: exercise
Description: * 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min
Study NCT04026516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAVA Device
Description: The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
Study NCT01712464 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxytocin vs. Placebo
Description: FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
Study NCT05315869 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical procedure for removal of the appendix
Study NCT00106535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4 mg/kg or 8 mg/kg IV/month every 4 weeks.
Study NCT00106535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV/month
Study NCT00106535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 10-25 mg/week
Study NCT00106535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25 mg/week
Study NCT03721965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
Study NCT03721965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
Study NCT04375696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyglucosamine L112
Description: Polyglucosamine; Ascorbic Acid; Tartaric Acid
Study NCT04375696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dicalcium Phosphate; Microcrystalline Cellulose; Iron Oxide (yellow, brown, and black); Magnesium Stearate; Silicon Dioxide
Study NCT00854295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGen LPS-Flex Mobile Bearing Knee
Description: Total Knee Replacement
Study NCT02321150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cautery
Description: * Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Relaxing incisions placed at the corners of the recipient site.~* Graft is slid into place~* Graft / host interface is gently dried with a Qtip~* Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~  * Power setting: 25.~ * Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~* Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~* Cautery is applied at the 4 apices of the graft then in between these points.
Study NCT02321150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures
Description: * Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~* Conjunctiva undermined at the recipient site.~* Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures
Study NCT00937885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implementation of reminiscence
Study NCT01653132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinum Toxin A
Description: Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
Study NCT01653132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
Study NCT04690062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brolucizumab-Dbll
Description: intravitreal injection of Brolucizumab (BEOVU)
Study NCT02945046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered per dose and schedule specified in the arm.
Study NCT02945046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study NCT00567112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg MK-0941 DFC (fasted)
Description: single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
Study NCT00567112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg MK-0941 OCT (after meal)
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
Study NCT00567112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mg MK-0941 OCT (before meal)
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
Study NCT00567112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg MK-0941 OCT (fasted)
Description: single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
Study NCT01663077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
Study NCT00425854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: high dose once daily
Study NCT03223272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reserpine
Description: Open label reserpine 0.1 mg pill orally
Study NCT01972334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: as explained in study arm
Study NCT01972334 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: salt water or saline will be given as placebo
Study NCT00540423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR 25mg
Description: SB-497115-GR 25mg tablet once a day
Study NCT00540423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SB-497115-GR 12.5mg matching placebo
Description: SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
Study NCT00540423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR 50 mg
Description: SB-497115-GR 25mg tablet x2 once a day
Study NCT03717805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POAM
Description: The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
Study NCT00876967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: metallic single use blade
Description: metallic single use blade
Study NCT00876967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plastic single use blade
Description: plastic single use blade
Study NCT00876967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metallic reusable blade
Description: metallic reusable blade
Study NCT03168659 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: HeartLight
Description: HeartLight Endoscopic Ablation System
Study NCT03168659 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ablation
Description: Pulmonary vein isolation ablation
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Participants will receive intravenous (IV) mosunetuzumab.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive polatuzumab vedotin via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polatuzumab Vedotin
Description: Participants will receive polatuzumab vedotin via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxumab
Description: Participants will receive rituxumab via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Participants will receive doxorubicin via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Participants will receive doxorubicin via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants will receive vincristine via IV.
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive oral prednisone.
Study NCT00982150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talampanel
Description: 50mg capsules tid
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive oral prednisone.
Study NCT02642718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
Study NCT02642718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
Study NCT03677141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab via IV.
Study NCT03747289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: performing exercises in a weight bearing posture
Description: 20 participants will perform exercises in a weight bearing posture
Study NCT02307968 — intervention group
Intervention type: OTHER
Intervention: insulin injection site
Description: insulin injected site between inner thigh and out thigh
Study NCT03747289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: performing exercises in a non weight bearing posture
Description: 20 participants will perform exercises in a non weight bearing posture
Study NCT00573950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: 50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
Study NCT03721471 — intervention group
Intervention type: OTHER
Intervention: Scoring of frailty
Description: 1. Patients will be scored by the Clinical frailty Scale~2. Patients' hand-grip-strength will be measured by a dynamometer.
Study NCT05800262 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic stability exercises
Description: A dynamic stability exercise program for daily home-exercise was applied during five physiotherapist led sessions distributed over seven weeks.
Study NCT02316223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supporting Asthma Management Behaviors in Aging Adults (SAMBA)
Description: The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
Study NCT02316223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporting Asthma Management Behaviors in Aging Adults (SAMBA)
Description: The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
Study NCT00446966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega Three Polyunsaturated fatty acids
Description: 2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
Study NCT00446966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omega Three Polyunsaturated fatty acids
Description: 2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
Study NCT03703154 — intervention group
Intervention type: DRUG
Intervention: Envarsus
Description: Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
Study NCT03703154 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: The patient's physician will prescribe drug according to standard practice.
Study NCT01169753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet every morning for 2 weeks
Study NCT01169753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Three 50 mg tablets orally every morning for 2 weeks.
Study NCT01943877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling root planing
Description: scaling root planing
Study NCT01943877 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: scaling root planing
Description: scaling root planing
Study NCT01943877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: experimental
Study NCT03084263 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Assisted Open Reduction Internal Fixation
Description: Surgical fixation of ankle fractures with use of arthroscopy.
Study NCT03084263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Reduction Internal Fixation
Description: Surgical fixation of ankle fractures.
Study NCT01167829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Testosterone
Description: Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
Study NCT01167829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: 300 ug/kg injection on Day 0
Study NCT01828125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycaemic hyperinsulinemic clamp
Description: A first catheter will be inserted for infusion of D-\[6,6-2H2\] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-\[6,6-2H2\] glucose. A third catheter will be inserted for sampling. D-\[6,6-2H2\] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
Study NCT02525445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
Study NCT02525445 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle \[20\]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin.
Study NCT02525445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: positive communication
Description: During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension.
Study NCT02525445 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: positive communication
Description: During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension.
Study NCT02525445 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neutral communication
Description: During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,
Study NCT02525445 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: neutral communication
Description: During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,
Study NCT01789463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self rehabilitation